Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the second leading
cause of cancer mortality worldwide. Incidence rates of liver cancer vary widely between …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …

Background No effective systemic therapy exists for patients with advanced hepatocellular
carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the …

Staging and treatment indication are relevant topics in the management of patients with
hepatocellular carcinoma (HCC) and for optimal results, they have to take into account liver …

Abstract Introduction The Asian Pacific Association for the Study of the Liver (APASL)
convened an international working party on the management of hepatocellular carcinoma …

Many guidelines for hepatocellular carcinoma (HCC) have been published and updated
globally. In contrast to other cancers, there is a range of treatment options for HCC involving …

The design of clinical trials in hepatocellular carcinoma (HCC) is complex because many
patients have concurrent liver disease, which can confound the assessment of clinical …